Navigation Links
Neuradiab in Medical News

Bradmer provides Phase III Neuradiab trial update and guidance

TSX: BMR TORONTO, Oct. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it held a pre-Phase III meeting with the U.S. Food and Drug ...

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid

...equally. We continue to evaluate opportunities to maximize the value of the neuradiab asset, however a substantial portion of the existing cash on hand will be u...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2009 first quarter operational and financial results

...luate strategic options. "Despite our pride in the progress made bringing neuradiab from a single-site Phase II program to a multicenter Phase III registration...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

...tinuing to evaluate strategic options. "We have successfully transitioned neuradiab from a Phase II compound with compelling results at a single site to a cGMP...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer implements cash conservation plan

...tends to maintain the ability to pursue business development strategies for neuradiab and is continuing to explore opportunities that would permit further develo...lment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

...l patient survival from 53 to 64 weeks. About neuradiab neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...

Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference

... form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency. Bradmer Pharmaceuticals ...

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

...ponse of newly diagnosed GBM patients treated with neuradiab as an adjunct to the current standard of care, con...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...

Bradmer announces 2008 third quarter operational and financial results

...ART Trial and successfully dosed patients with neuradiab at multiple sites; - Announced new data from the...llow a two week extension of the shelf life of neuradiab beyond the current six-day specification; and ...y to provide a definitive answer on the benefit of neuradiab in the newly diagnosed GBM population." The Phas...

Bradmer to present at Rodman & Renshaw Healthcare Conference

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Neuradiab in Medical Technology

Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings

TSX: BMR TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that new research published by an independent team in Basel, Switzerland validates tenascin as ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

...ical trial, termed the GLASS-ART Trial, evaluating neuradiab as an adjunct therapy to the current standard of c...e control arm. "These PFS data from the Phase II neuradiab trials exceed the results achieved in any other cl...nt of median overall survival, the opportunity for neuradiab to demonstrate a patient benefit via the parameter...
Neuradiab in Biological Technology

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy for patien...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Other Tags
(Date:10/25/2014)... supply to an arm or a leg before heart surgery ... to a new study. "During heart surgery we ... be able to operate on it. After some time without ... energy because it doesn,t get oxygen. When we shut off ... arm or a leg, the body prepares for an upcoming ...
(Date:10/25/2014)... -- Researchers who discovered antibiotics in farmed and ... concern. The use of antibiotics in animals, ... contribute to the development of antibiotic-resistant bacteria that ... the study. Each year in the United ... and kill about 23,000, according to the Infectious ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
(Date:10/22/2014)... On Saturday, October 25, 2014, the Brownsville Community ... and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. ... for better health and wellness for people of all ages ... to the public, will be held at Dean Porter Park, ... 1:00 pm. , “¡Vive tu Vida! Get Up! Get ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Isabel ... of Allied Health Professions (ASAHP) Conference on October 22-24 ... CEO will participate in a panel discussion on Technology ... , Isabel Healthcare provides a diagnostic decision support tool ... the diagnosis skills of students and clinical learners. The ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
(Date:10/14/2014)... published in Cancer Research shows SIRT6—a protein ... cancers—can promote the development of skin cancers by turning ... of sun-damaged skin cells. , Previously considered protective, SIRT6 ... sirtuins that help regulate genomic stability and prevent some ... repair DNA damage, which can lead to cancer. This ...
(Date:10/14/2014)... the house fly genome for the first time, revealing ... insect that thrives in pathogen-rich dung piles and garbage ... journal Genome Biology , will increase understanding of ... quickly adapt to resist insecticides, which could lead to ... carry and transmit more than 100 human and animal ...
(Date:10/14/2014)... Mount Sinai-led research team has discovered a new kind of ... a cell that lines liver blood vessels, according to a ... . The existence of such a cell type contradicts current ... embryo, and may hold clues to origins of, and future ... from a single cell into a complex being made up ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
Other Contents